PMID- 27862865
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20180424
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 90
IP  - 1
DP  - 2017 Jul
TI  - Long-term clinical and angiographic outcomes of percutanenous coronary
      intervention with everolimus-eluting stents for the treatment of cardiac
      allograft vasculopathy.
PG  - 48-55
LID - 10.1002/ccd.26830 [doi]
AB  - BACKGROUND: Percutaneous coronary intervention (PCI) with bare-metal and
      first-generation drug-eluting stents (DES) for cardiac allograft vasculopathy
      (CAV) is associated with unexpectedly high restenosis rates and target lesion
      revascularization (TLR). Long-term outcomes of stenting for CAV using
      second-generation everolimus-eluting stents (EES) are not established. OBJECTIVE:
      To evaluate clinical and angiographic outcomes of CAV stenting with EES. METHODS:
      Patients who underwent PCI with EES for CAV were studied. Surveillance
      angiography was performed at 6-12 months post-PCI and as indicated. Patient
      survival, freedom from MACE, binary restenosis, TLR, target vessel
      revascularization (TVR), and non-TVR are reported. RESULTS: One-hundred and
      thirty two EES were placed in 113 discrete lesions in 48 patients. Pre-PCI
      stenosis was 82.1 +/- 12.4%, and average stent length and diameter were 16.9 +/- 
      5.7 and 3.0 +/- 0.6 mm, respectively. Mean follow-up was 30.7 +/- 18.8 months.
      Time from transplantation to PCI was 9.9 +/- 5.1 years. Post-PCI survival at 1
      (93.5 +/- 3.6%), 2 (91.0 +/- 4.3%), and 3 years (83.8 +/- 6.3%), and freedom from
      MACE (87.2 +/- 4.9%, 82.3 +/- 5.7%, 75.8 +/- 6.9%) were high. Binary restenosis
      at 1 (3.0 +/- 1.7%), 2 (6.9 +/- 3.2%), and 3 years (10.0 +/- 4.3%) mirrored
      expected rates with EES use in native CAD. One-, two-, and three-year rates of
      TLR (5.1 +/- 2.5%, 14.3 +/- 4.6%, and 21.2 +/- 6.3%), TVR (17.1 +/- 4.5%, 39.0
      +/- 6.9%, and 46.2 +/- 7.8%), and NTVR (26.3 +/- 5.4%, 55.4 +/- 7.0%, and 58.0
      +/- 7.0%) remain high. Diabetes was associated with an increased hazard ratio for
      binary restenosis 6.084 (95% CI 1.271-29.133, P = 0.024). CONCLUSIONS: PCI
      strategy using EES in the treatment of CAV was associated with a low binary
      restenosis rate, a high survival rate, and a high rate of freedom from MACE.
      However, at 3 years, TLR and TVR rates appeared similar to rates observed with
      first-generation DES. (c) 2016 Wiley Periodicals, Inc.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Cheng, Richard
AU  - Cheng R
AUID- ORCID: http://orcid.org/0000-0003-2552-6773
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Vanichsarn, Christopher
AU  - Vanichsarn C
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Patel, Jignesh K
AU  - Patel JK
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Currier, Jesse
AU  - Currier J
AD  - Division of Cardiology, VA Greater Los Angeles Healthcare System, Los Angeles,
      California.
FAU - Chang, David H
AU  - Chang DH
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Kittleson, Michelle M
AU  - Kittleson MM
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Makkar, Raj
AU  - Makkar R
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Kobashigawa, Jon A
AU  - Kobashigawa JA
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Azarbal, Babak
AU  - Azarbal B
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161110
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Cardiovascular Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Allografts
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - *Coronary Angiography
MH  - Coronary Artery Disease/*diagnostic imaging/etiology/*therapy
MH  - Coronary Restenosis/diagnostic imaging/etiology
MH  - Coronary Vessels/*diagnostic imaging
MH  - Disease-Free Survival
MH  - *Drug-Eluting Stents
MH  - Everolimus/*administration & dosage/adverse effects
MH  - Female
MH  - Heart Transplantation/*adverse effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/adverse effects/*instrumentation
MH  - Predictive Value of Tests
MH  - Prosthesis Design
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - CAD
OT  - DES
OT  - PCI
OT  - transplantation
EDAT- 2016/11/20 06:00
MHDA- 2018/04/25 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/06/10 00:00 [received]
PHST- 2016/09/21 00:00 [revised]
PHST- 2016/10/08 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
AID - 10.1002/ccd.26830 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2017 Jul;90(1):48-55. doi: 10.1002/ccd.26830. Epub
      2016 Nov 10.